Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen, is a plasmid (supercoiled circular DNA) encoding
gene p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment,
enhances the anti-cancer effects of other therapies (e.g. chemotherapy),
mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen.
The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
Based on these successful results, we initiated Phase II Clinical Trials outside of the
United States
, and are now preparing Phase II Clinical Trials within the US.
 

Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen, is a plasmid (supercoiled circular DNA) encoding
gene p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment,
enhances the anti-cancer effects of other therapies (e.g. chemotherapy),
mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen.
The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
Based on these successful results, we initiated Phase II Clinical Trials outside of the
United States
, and are now preparing Phase II Clinical Trials within the US.
Elegan is a plasmid (Circular DNA) Encoding Gene P62/SQSTM1

Clinical Trials


The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen. The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients. Based on these successful results, we initiated Phase II Clinical Trials outside of the United States, and are now preparing Phase II Clinical Trials within the US.

Elegan is a plasmid (Circular DNA) Encoding Gene P62/SQSTM1

Completed phase I/IIa clinical trial



Elenagen: Case Study

Elenagen: Case Study



International Clinical Trials 2019

International Clinical Trials 2019



US clinical trials

US clinical trials



Elegan is a plasmid (Circular DNA) Encoding Gene P62/SQSTM1

Completed phase I/IIa clinical trial



Elenagen: Case Study

Elenagen: Case Study



International Clinical Trials 2019

International Clinical Trials 2019



US clinical trials

US clinical trials



Alexander Shneider

Alexander
Shneider,
Ph.D.


Founder and CEO
BoD Chairman



Over 25 years of biotech and entrepreneurial experience. Currently Senior Research Fellow of molecular biology at University of Ariel, Israel; editorial board member for journals Aging and Cell Cycle, advisor at We Fund Health. The past achievements and activities include but are not limited to drug development from concept to market authorization, patents in all major jurisdictions, advisory role for successful exits, consulting for Fortune 100 companies, establishing and leading international R&D consortia, senior authorship in papers and books.
Vlad Gabai, Ph.D.

Vlad
Gabai,
Ph.D.


VP of R&D




Over 30 years of successful discovery and development experience and problem-solving skills in R&D of anti-cancer drugs from bench to bedside. Over 80 papers, over 4,000 references. Past academic appointments with Boston University and Boston Biomedical Research Institute.
Mr. Charles Legg

Mr.
Charles
Legg


COO




Over 20 years of successful biotech and big pharma experience ranging from program & portfolio manager at the international pharmaceutical company, Shire Pharmaceuticals, to the first full-time employee of the gene therapy startup, Solid Ventures. Successful projects in molecular diagnostics, drug discovery from early POC to pivotal clinical trials, from commercial launching to global expansion, from early seed funding to two $100MM+ IPOs. Focus on gene therapy and immuno-oncology.
Ilya Lapshin-1

Ilya
Lapshin,
JD


General Council




18 years of legal experience in a large New York law firm and two Massachusetts-based boutique firms helping startups and big corporate clients. Between a double major at MIT, Physics with Electrical Engineering and Math, and Boston University Law School, successful entrepreneurial and startup experience including a lucrative exit from a business, which Ilya started as a co-founder as soon as he came to the US.
Franco Venanzi

Franco
Venanzi,
Ph.D.


Director of Basic Research



Over 30 years of biomedical research, over 20 years of tenured faculty professorship at University of Camerino, Italy, where was Head of the Translational Biology Laboratory, 20 years of service as editor-in-chief, editorial board member and a reviewer for vaccination and immunobiology journals.
Hong Lee, MD, MBA, MPH, MS

Hong Li,
MD, MBA,
MPH, MS


Interim Clinical Director




Over 20 years extensive global clinical development and medical affairs strategic experience, outstanding proven track records in US, Europe, and Asian-pacific. As a clinical/medical/project lead, led global cross function teams to develop clinical and/or medical plans, conduct international trials across multiple therapeutic indications and cross phases 1-4 and postmarketing, to meet scientific, regulatory and commercial needs, with high quality and in a timely/on budget/scientifically responsible fashion.
Michael Burns, МСЕЕ

Michael Burns, МСЕЕ





Michael Burns has more than 20 years of experience in technology start-ups and private equity. He also has been a Partner at Alara Capital, a core advisor at Gauss Ventures, a Managing Director at Guggenheim Partners, and a Managing Director at TL Ventures. He has deep operating experience and has been part of many successful companies where he has been a co-founder, seed investor or senior executive including Agere (Agere Systems), Ciclon Semiconductor (Texas Instruments), and Traffic.com (Nokia). Michael graduated UPenn (engineering), and Warton Business School (finance) as a Benjamin Franklin Scholar.

Andrey-Morozov

Andrew Morozov
Ph.D., MBA





Andrew Morozov has more than 25 years of experience. Senior management positions with Fuji-Keizai, IBM Watson, A.T. Kearney, Gartner. Co-founded several startup companies: Decision Drivers, Amhurst Capital, Tundrex. Investment management experience: TL Ventures, Amhurst Capital, Cisco Systems, VEB Innovations Venture Fund resulting in 12 successful exits including Aberdeen Group, Grid Dynamics, Intellon, Mobix Chip, Datadvance. Andrew obtained M.Sc. with magna cum laude and Ph.D. Moscow Institute of Physics and Technology, and an M.B.A from the Wharton School at UPenn. In 2012, Andrew managed a $1M seed investment in CureLab Oncology.

SCIENTIFIC ADVISORY BOARD

Aaron Ciechanover
– Nobel Prize in Chemistry 2004, Technion, Haifa, Director of Cancer Control Center, Israel
David Shulkin, MD
– In the past served as the 9th US Secretary of Veterans Affairs, President & CEO of Beth Israel Medical Center, President of Morristown Medical Center and VP of Atlantic Health System Accountable Care Organization, Chief Medical Officer of the University of Pennsylvania Hospital; currently serving as an editorial board member of several journals, including Journal of the American Medical Association and a consultant
Kim Lewis
– Distinguished Professor of Biology, Director of Antimicrobial Drug Discovery Center, Northeastern University
Michael Sherman
– Professor of Biochemistry, Boston University School of Medicine
Stuart Calderwood
– Associate Professor, Scientific Director of Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School
Adolfo García-Sastre
– Mount Sinai Hospital, Icahn school of Medicine; Professor of Microbiology, Professor of Medicine and Infectious Diseases, Director, Global Health and Emerging Pathogens Institute, Director, Center for Research on Influenza Pathogenesis
Roland Baron, DDS, PhD
– Professor of Oral Medicine, Infection, and Immunity and Chair of the Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, U.S.
Dr. Marvin Gilmore, Jr.
– Board member for Mount Auburn Hospital, UMass Boston, New England Conservatory of Music, New Market Business Association; Trustee for Boston Local Development Corporation (BLDC)
Givi Topchishvili
–   Serial entrepreneur, investor, inventor, author with 30 years of successful business track record across numerous sectors.
Prof. Sergei Krasny, MD, PhD
- Deputy Director for Research, N.N. Alexandrov National Cancer Center, Minsk, Belarus

Contact us: info@curelab.com